Agalsidase Alfa Biosimilar – Alpha-D-galactosidase A – Research Grade

Description of Agalsidase Alfa Biosimilar - Alpha-D-galactosidase A - Research Grade

Introduction

Agalsidase Alfa Biosimilar, also known as Alpha-D-galactosidase A, is a recombinant form of the enzyme alpha-galactosidase A. This biosimilar is used as a therapeutic target for the treatment of Fabry disease, a rare genetic disorder caused by a deficiency of this enzyme. In this article, we will discuss the structure, activity, and application of Agalsidase Alfa Biosimilar in detail.

Structure of Agalsidase Alfa Biosimilar

Agalsidase Alfa Biosimilar is a protein-based drug that is produced by recombinant DNA technology. It is a biosimilar of the brand-name drug, Fabrazyme. The protein is composed of 429 amino acids and has a molecular weight of approximately 50 kDa. It is a glycoprotein, meaning it has sugar molecules attached to it. The sugar molecules are important for the stability and activity of the enzyme.

The structure of Agalsidase Alfa Biosimilar is similar to the natural form of alpha-galactosidase A enzyme found in the human body. It consists of two identical subunits, each containing three domains – a catalytic domain, a lectin-like domain, and a proline-rich domain. The catalytic domain is responsible for the enzyme’s activity, while the lectin-like domain helps in binding to its substrate. The proline-rich domain is important for the stability of the enzyme.

Activity of Agalsidase Alfa Biosimilar

Agalsidase Alfa Biosimilar works by replacing the deficient or defective alpha-galactosidase A enzyme in Fabry disease. The enzyme is responsible for breaking down a type of fat called globotriaosylceramide (Gb3). In patients with Fabry disease, this fat accumulates in various organs, leading to organ damage. Agalsidase Alfa Biosimilar helps in breaking down Gb3, preventing its accumulation and reducing the symptoms of the disease.

The activity of Agalsidase Alfa Biosimilar is measured in units, with one unit being defined as the amount of enzyme that catalyzes the breakdown of one micromole of Gb3 per hour at 37°C. The recommended dose of Agalsidase Alfa Biosimilar for Fabry disease is 1 mg/kg given every two weeks via intravenous infusion.

Application of Agalsidase Alfa Biosimilar

Agalsidase Alfa Biosimilar is indicated for the long-term treatment of patients with Fabry disease. It is used to improve symptoms such as pain, gastrointestinal problems, and skin lesions. It is also effective in preventing the progression of kidney and heart damage in patients with Fabry disease.

In addition to its therapeutic use, Agalsidase Alfa Biosimilar is also used in research and development. It is commonly used as a tool in studying the structure and function of alpha-galactosidase A enzyme and its role in Fabry disease. The biosimilar form of the drug is more cost-effective compared to the brand-name drug, making it a preferred choice for research purposes.

Conclusion

Agalsidase Alfa Biosimilar, also known as Alpha-D-galactosidase A, is a recombinant form of the enzyme alpha-galactosidase A. It is used as a therapeutic target for the treatment of Fabry disease, a rare genetic disorder caused by a deficiency of this enzyme. The biosimilar has a similar structure and activity to the natural form of the enzyme and is effective in improving symptoms and preventing organ damage in patients with Fabry disease. It is also used in research and development due to its cost-effectiveness.